Industry: Life Sciences

Life sciences fundraising advisory

Biotech, pharma and medtech investors fund milestones, not science alone. We turn your data into the deck, model and target list that specialist funds expect.

  • Investor lists and funding data for drugs, devices and tools
  • Decks and models built around trial milestones
  • Waveup prepares investor materials for life sciences companies: $3B+ raised for 600+ startups since 2014

In short

What is life sciences fundraising advisory?

Life sciences fundraising advisory is help raising money for a biotech, pharma, medtech or research-tools company. The advisor builds what investors will test: the deck, the financial model, the valuation and the investor list. Venture investors put $30.5B into biopharma startups in 2025. They pay for milestones, so your case must show what each round proves.

Who it's for
Biotech, pharma, medtech and research-tools companies, pre-seed to Series D+
What we build
Investor deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 5 November 2026. Sources are under each section.

Is life sciences funding coming back in 2026?

Yes, for companies with data or a clear path to it. Venture money and IPOs are rising again, but investors back fewer, larger rounds.

The opportunity

Big drugmakers must replace medicines that lose patent protection. Many of the replacements come from younger companies.

  • Patent expiries open a growth gap that deals must fill
  • AI is changing how new drug candidates are found
  • Medtech buyers keep acquiring device makers

The problem

Investors now back fewer companies with bigger cheques. In 2026, Series B and later rounds took about 72% of biopharma venture money.

Market size

How big is the life sciences market, and what is driving it?

Start with medicines. IQVIA expects global spending on them to pass $2.6 trillion by 2030. Four forces shape where investors put their money:

  • Patent expiries: EY projects a $370B growth gap by 2032 as blockbusters lose exclusivity
  • Dealmaking: life sciences M&A reached $240B in 2025, by EY's count
  • AI: EY counts a 256% rise in the potential value of deals for AI platforms
  • Rare diseases: half of the FDA's new drugs in 2025 were for rare diseases
FDA novel drug approvals: 22 in 2016, 59 in 2018 and 46 in 2025, about 47 a year on average.

Life sciences in 2026, in six numbers

$232B

biotech industry revenue in 2025, up 13% on 2024

43%

of the FDA's new drugs in 2025 were first-in-class, working in a new way

70%

of the FDA's new drugs in 2025 were approved in the US first

$221.1B

announced value of biopharma licensing deals in 2026, to September

$7.5B

raised by 22 biopharma IPOs in 2026, more than in any full year from 2022 to 2025

$64.1B

of medtech M&A in 2026 to September, already more than in all of 2025

Venture capital

How much life sciences venture capital is there in 2026?

Biopharma venture funding grew two years running, to $30.5B in 2025. J.P. Morgan expects about $33B in 2026 if the current pace holds.

Venture funding worldwide: biopharma $28.2B in 2022, $30.5B in 2025 and $23.9B in 2026 to September; medtech $15.4B, $13.1B and $8.0B.
574

biopharma venture rounds in 2025, down from 829 in 2021

68

biopharma rounds of $100M or more in 2026, to 30 September

$6.6B

raised by seed and Series A biopharma companies in 2026, across 170 rounds

Who invests in life sciences startups?

Specialist biotech VCs, multi-stage funds, medtech investors, lenders and EU grants. Seven examples follow; our list of life sciences venture capital firms has more.

Investor
Type and base
Life sciences companies backed
Stage or cheque
Atlas Venture
Biotech VC and incubator, Cambridge, MA
Intellia Therapeutics, Dyne Therapeutics, Kymera Therapeutics
Not stated
Forbion
Biotech VC, Naarden (Netherlands)
Azafaros, VectorY
Pre-seed to clinical-stage growth
RA Capital Management
Multi-stage investor, Boston
Moderna, Natera, Apogee Therapeutics
Seed to IPO and follow-ons
Novo Holdings
Holding and investment company, Denmark
Myricx Bio, Nalu Medical, Expedition Therapeutics
Early science to commercial stage
Vensana Capital
Medtech VC and growth equity, Minneapolis
Inari, CVRx, Relievant
Development and commercial stage
Hercules Capital
Venture lender, San Mateo, CA
Madrigal Pharmaceuticals, Axsome Therapeutics, TransMedics
Venture loans; stage not stated
EIC Accelerator
EU grants and equity
Start-ups and SMEs in any field of technology
Grant up to €2.5M; equity €1M to €10M

Investor database

Biotech investors in our database

The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by biotech investments

  • Investments by industry

    • Healthtech & Wellness47%
    • Biotech26%
    • Pharma20%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Chicago, United States
    Invests in
    USA

    502 investments in total, 23 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness41%
    • Biotech36%
    • Pharma18%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Boston, United States
    Invests in
    USA

    141 investments in total, 22 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness38%
    • Biotech33%
    • Pharma17%
    Rounds
    SeedSeries ASeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    San Francisco, United States
    Invests in
    USA

    196 investments in total, 20 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness44%
    • Biotech27%
    • Pharma15%
    Rounds
    Series ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Boston, United States

    439 investments in total, 18 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness46%
    • Biotech25%
    • Pharma16%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    United States
    Invests in
    Israel, Europe, USA +1

    231 investments in total, 17 tagged Biotech.Open the full fund profile

From our investor database.

Why do life sciences startups struggle to raise?

Our Fundraising 2025 study asked 56 VCs why they pass. Burn and missed milestones were among the top reasons. In life sciences, both weigh more, because revenue comes late.

Most drugs fail in trials

Most drugs that enter human trials never reach patients. In BIO's 2011–2020 data, only 7.9% of Phase I drugs won approval.

What investors ask

  • Which result does this round buy, and what is the company worth after it?

What your deck shows

  • One milestone the money reaches, with a date
  • Cash runway past that readout

Fewer first cheques

Investors want data before they lead a first round. First-time biopharma financings fell to $1.7B in Q3 2026, the lowest since Q3 2025.

What investors ask

  • Why fund you now, before the data, rather than after it?

What your deck shows

  • What each step removes from the risk
  • Who could lead your next round, and why

Competition from China

Big drugmakers now license many drugs first developed in China. In 2026, those made up 51% of their licensing deals with large upfront payments.

What investors ask

  • Why license your asset if a cheaper one exists elsewhere?

What your deck shows

  • What sets your molecule apart: mechanism, data, patents
  • A development plan that is fast and lean

Big deal values, little cash upfront

Licensing deals announce big totals, but most of the money depends on milestones. Upfront cash was just 6% of announced biopharma licensing value in 2026.

What investors ask

  • What would a partner really pay, and when?

What your deck shows

  • Comparable deals by upfront cash, not headline value
  • A partnering plan tied to your data readouts

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Life sciences
11%
of our projects on record are in healthcare and life sciences

Life sciences fundraising advisory FAQ

What does a life sciences fundraising advisor do?
An advisor builds the case that investors will test. For a life sciences company, that starts with a deck that explains the science simply. It also means a model tied to trial milestones, a valuation and a list of investors who fund your stage. We set up the outreach too. Our biotech pitch deck guide shows what goes in.
How do life sciences startups get funding?
Is life sciences funding coming back in 2026?
Should you hire an investment bank or a fundraising advisor?
How are life sciences startups valued?
How much does life sciences fundraising advisory cost?

Industries we work with

Pharmaceuticals

All industries

Raising for a life sciences company?

Send us your stage and your next milestone. We'll tell you which questions investors will ask first.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?